1. Canada Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
GeneTether Therapeutics Inc.

GeneTether Therapeutics Inc.

GNTTF
GeneTether Therapeutics Inc.US flagOther OTC
0.01
USD
-0.02
- -
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
-0.04
-0.04
-0.01
- -
-0.01
Free Cash Flow per Basic Share
- -
-0.02
-0.03
-0.01
- -
-0.01
Dividend per Share
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
-0.01
0.01
- -
- -
-0.02
Tangible Book Value per Share
- -
- -
0.04
0.03
- -
0.03
Basic Weighted Avg Shares
48
46
43
46
- -
39
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
Net Income, GAAP
- -
-2
-2
-1
-1
-1
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
Working Capital
- -
- -
2
1
1
1
LT Debt
- -
- -
- -
- -
- -
- -
Total Equity
- -
- -
2
1
1
1
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Jun'24
Sep'24
Dec'24
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
39
39
76
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Jun'24
Sep'24
Dec'24
Total Current Assets
1
1
1
Cash, Cash Equivalents & STI
1
1
1
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
- -
- -
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-19.17%
Free Cash Flow
- -
- -
0.23%
Net Income, GAAP
- -
- -
-19.97%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
-0.01
-0.01
-0.01
- -
-0.04
2023
- -
- -
- -
- -
-0.01
2024
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -

Company Description

APIChatGPT
Sector
Healthcare
Industry
Biotechnology
Address
Canada
IPO Date
Oct 14, 2022
Similar Companies
OKYO Pharma Limited (OKYO.L)
Nicox S.A. (COX.PA)
Hemogenyx Pharmaceuticals Plc (HOPHF)
Pharvaris N.V. (PHVS)
China Resources Boya Bio-pharmaceutical Group Co., Ltd. (300294.SZ)
Innate Pharma S.A. (IPHA)
Business
GeneTether Therapeutics Inc. (CSE: GTTX, OTC: GNTTF), formerly focused on genetic medicines, now develops oncology therapies following its January 2025 name change to Rize Oncology Inc.; headquartered in Kelowna, British Columbia, Canada, and founded in 2018, the company operates in the biopharmaceutical sector targeting rare cancers and proliferative diseases. Core offerings center on STS-201, a small-molecule drug candidate exclusively licensed from EGB Ventures in late 2024, which blocks cell division at the late G2/M boundary to enhance radiation sensitivity, normalize tumor vasculature, improve oxygenation, and reduce metastasis in soft tissue sarcoma (STS) and other cancers; the prior proprietary GeneTether platform technology for high-efficiency genome editing and gene correction remains part of its foundational intellectual property, including U.S. patents granted in 2022. Recent strategic shifts include the October 2024 binding term sheet for the STS-201 license and a C$250,000-C$500,000 private placement financing, both approved by shareholders in December 2024; engagement of John Rothman, Ph.D., as consulting Chief Scientific Officer with over 30 years in drug development; and laboratory expansion in the Bay Area in 2022 to accelerate R&D, reflecting a pivot from broad genetic therapies to oncology-focused assets with potential Orphan Drug status for STS.